Free Trial

SciSparc (SPRC) Competitors

SciSparc logo
$7.38 +0.19 (+2.64%)
Closing price 04:00 PM Eastern
Extended Trading
$7.36 -0.02 (-0.27%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

SPRC vs. FLGC, ALLR, MTEX, EDSA, PMN, SNPX, HOOK, LEXX, NEUP, and ERNA

Should you be buying SciSparc stock or one of its competitors? The main competitors of SciSparc include Flora Growth (FLGC), Allarity Therapeutics (ALLR), Mannatech (MTEX), Edesa Biotech (EDSA), Promis Neurosciences (PMN), Synaptogenix (SNPX), HOOKIPA Pharma (HOOK), Lexaria Bioscience (LEXX), Neuphoria Therapeutics (NEUP), and Ernexa Therapeutics (ERNA). These companies are all part of the "pharmaceutical products" industry.

SciSparc vs. Its Competitors

SciSparc (NASDAQ:SPRC) and Flora Growth (NASDAQ:FLGC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

25.1% of SciSparc shares are owned by institutional investors. Comparatively, 36.0% of Flora Growth shares are owned by institutional investors. 1.5% of SciSparc shares are owned by company insiders. Comparatively, 12.6% of Flora Growth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Flora Growth has a consensus price target of $4.00, suggesting a potential upside of 525.59%. Given Flora Growth's stronger consensus rating and higher possible upside, analysts clearly believe Flora Growth is more favorable than SciSparc.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
SciSparc
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Flora Growth
0 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.50

SciSparc has higher earnings, but lower revenue than Flora Growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SciSparc$1.31M2.99-$6.28MN/AN/A
Flora Growth$59.51M0.24-$15.91M-$0.98-0.65

In the previous week, SciSparc had 1 more articles in the media than Flora Growth. MarketBeat recorded 2 mentions for SciSparc and 1 mentions for Flora Growth. Flora Growth's average media sentiment score of 1.90 beat SciSparc's score of 0.93 indicating that Flora Growth is being referred to more favorably in the news media.

Company Overall Sentiment
SciSparc Positive
Flora Growth Very Positive

SciSparc has a net margin of 0.00% compared to Flora Growth's net margin of -24.85%. SciSparc's return on equity of 0.00% beat Flora Growth's return on equity.

Company Net Margins Return on Equity Return on Assets
SciSparcN/A N/A N/A
Flora Growth -24.85%-216.49%-45.56%

SciSparc has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Flora Growth has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500.

Summary

Flora Growth beats SciSparc on 8 of the 14 factors compared between the two stocks.

Get SciSparc News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SPRC vs. The Competition

MetricSciSparcMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.84M$2.45B$5.57B$9.31B
Dividend YieldN/A1.79%4.23%4.03%
P/E RatioN/A9.1928.6119.73
Price / Sales2.99587.68412.31173.11
Price / CashN/A164.3436.0257.96
Price / Book0.414.698.235.67
Net Income-$6.28M$30.99M$3.23B$257.79M
7 Day Performance4.83%0.60%-0.01%0.52%
1 Month Performance12.42%7.93%5.61%8.84%
1 Year Performance-56.02%-5.48%26.52%14.18%

SciSparc Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SPRC
SciSparc
0.9277 of 5 stars
$7.38
+2.6%
N/A-58.2%$3.84M$1.31M0.004News Coverage
Gap Up
FLGC
Flora Growth
2.6141 of 5 stars
$0.68
-1.5%
$4.00
+489.1%
-39.9%$15.57M$53.26M-0.70280Positive News
ALLR
Allarity Therapeutics
0.4525 of 5 stars
$1.03
-1.9%
N/A-83.1%$15.53MN/A0.0010News Coverage
MTEX
Mannatech
1.3774 of 5 stars
$8.14
-4.2%
N/A+14.8%$15.47M$117.87M-81.40250
EDSA
Edesa Biotech
2.2463 of 5 stars
$2.16
-1.8%
$5.00
+131.4%
-48.5%$15.17MN/A-1.3620Positive News
Gap Up
PMN
Promis Neurosciences
3.0869 of 5 stars
$0.44
-15.0%
$4.33
+880.4%
-79.3%$14.48MN/A-8.865News Coverage
Analyst Forecast
Analyst Revision
Gap Down
High Trading Volume
SNPX
Synaptogenix
0.3112 of 5 stars
$10.38
+15.5%
N/A+130.2%$14.43MN/A-1.034Positive News
High Trading Volume
HOOK
HOOKIPA Pharma
3.0568 of 5 stars
$1.18
-2.1%
$4.50
+283.0%
-80.2%$14.32M$43.95M-0.20160Positive News
LEXX
Lexaria Bioscience
1.9491 of 5 stars
$0.81
-2.4%
$5.00
+514.3%
-72.0%$14.29M$460K-1.387
NEUP
Neuphoria Therapeutics
2.215 of 5 stars
$7.60
-1.3%
$21.00
+176.3%
N/A$14.29M$15.66M0.00N/A
ERNA
Ernexa Therapeutics
0.5651 of 5 stars
$1.92
-2.3%
N/A-93.9%$14.10M$535K-0.2310Gap Up

Related Companies and Tools


This page (NASDAQ:SPRC) was last updated on 7/16/2025 by MarketBeat.com Staff
From Our Partners